Graney & King’s AbbVie ABBV Stock Holding History

Graney & King’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$91.8K	Sell	365 -375	-51%	-$80.7K	0.03%	115
2026 Q1	$161K	Buy	740 +5	+0.7%	+$1.11K	0.09%	78
2025 Q4	$168K	Buy	735 +5	+0.7%	+$1.14K	0.1%	73
2025 Q3	$169K	Sell	730 -258	-26%	-$52.5K	0.12%	67
2025 Q2	$183K	Sell	988 -318	-24%	-$59.1K	0.12%	59
2025 Q1	$274K	Sell	1,306 -187	-13%	-$36.4K	0.2%	48
2024 Q4	$265K	Buy	+1,493	New	+$274K	0.2%	46

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Graney & King's ABBV Position: Q2 2026 in Review

Graney & King reduced its AbbVie (ABBV) stake by 51% in Q2 2026, selling an estimated $80.7K and leaving 365 shares worth $91.8K. The position accounts for 0.03% of the portfolio, ranked #115.

Graney & King first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. The position peaked at $274K in Q1 2025. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Graney & King held 365 shares of AbbVie worth $91.8K as of Q2 2026.
Graney & King sold 375 AbbVie shares in Q2 2026, an estimated $80.7K.
AbbVie made up 0.03% of Graney & King's portfolio in Q2 2026, its #115 holding.
Graney & King first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
Graney & King's AbbVie position peaked at $274K in Q1 2025.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Graney & King's 13F filing for Q2 2026, filed 7 Aug 2026.